|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
103.12(B) |
Last
Volume: |
259,279 |
Avg
Vol: |
765,410 |
52
Week Range: |
$692.45 - $993.95 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
168,566 |
236,471 |
279,472 |
438,206 |
Total Sell Value |
$164,437,486 |
$226,505,895 |
$262,153,799 |
$373,147,368 |
Total People Sold |
8 |
14 |
16 |
18 |
Total Sell Transactions |
15 |
42 |
60 |
120 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mccourt Marion |
EVP Commercial |
|
2023-06-01 |
4 |
AS |
$736.00 |
$184,000 |
D/D |
(250) |
20,553 |
|
14% |
|
Ryan Arthur F |
Director |
|
2023-06-01 |
4 |
AS |
$730.03 |
$73,542 |
D/D |
(100) |
18,847 |
|
14% |
|
Schleifer Leonard S |
President & CEO |
|
2023-05-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
53,807 |
64,985 |
|
- |
|
Schleifer Leonard S |
President & CEO |
|
2023-05-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
53,807 |
0 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2023-05-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,326 |
59,421 |
|
- |
|
Ryan Arthur F |
Director |
|
2023-05-01 |
4 |
AS |
$802.67 |
$80,533 |
D/D |
(100) |
18,947 |
|
3% |
|
Brown Michael S |
Director |
|
2023-04-21 |
4 |
AS |
$798.42 |
$2,451,149 |
D/D |
(3,070) |
1,247 |
|
4% |
|
Brown Michael S |
Director |
|
2023-04-21 |
4 |
OE |
$520.01 |
$1,596,431 |
D/D |
3,070 |
4,317 |
|
- |
|
Ryan Arthur F |
Director |
|
2023-04-03 |
4 |
AS |
$816.58 |
$81,931 |
D/D |
(100) |
19,047 |
|
-2% |
|
Vagelos P Roy |
Director |
|
2023-04-03 |
4 |
GD |
$0.00 |
$0 |
I/I |
259 |
125,493 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2023-04-03 |
4 |
AS |
$818.80 |
$900,680 |
D/D |
(1,100) |
20,803 |
|
-2% |
|
Mccourt Marion |
EVP Commercial |
|
2023-04-03 |
4 |
OE |
$372.46 |
$409,706 |
D/D |
1,100 |
21,903 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2023-03-28 |
4 |
AS |
$818.81 |
$829,233 |
D/D |
(1,007) |
31,922 |
|
-6% |
|
Landry Robert E |
EVP Finance CFO |
|
2023-03-27 |
4 |
AS |
$819.47 |
$150,372 |
D/D |
(183) |
32,929 |
|
-7% |
|
Landry Robert E |
EVP Finance CFO |
|
2023-03-27 |
4 |
D |
$825.17 |
$2,304,700 |
D/D |
(2,793) |
33,112 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2023-03-27 |
4 |
OE |
$378.98 |
$1,442,476 |
D/D |
3,800 |
35,316 |
|
- |
|
Bassler Bonnie L |
Director |
|
2023-03-24 |
4 |
AS |
$818.00 |
$1,014,320 |
D/D |
(1,240) |
1,247 |
|
-6% |
|
Bassler Bonnie L |
Director |
|
2023-03-24 |
4 |
OE |
$380.95 |
$472,378 |
D/D |
1,240 |
2,487 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2023-03-23 |
4 |
D |
$801.59 |
$5,404,320 |
D/D |
(6,742) |
27,471 |
|
- |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2023-03-23 |
4 |
OE |
$270.43 |
$2,704,300 |
D/D |
10,000 |
34,213 |
|
- |
|
Yancopoulos George |
President and Chief Scientific |
|
2023-03-23 |
4 |
AS |
$800.59 |
$2,940,374 |
I/I |
(3,656) |
196,848 |
|
-9% |
|
Vagelos P Roy |
Director |
|
2023-03-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
312,578 |
|
- |
|
Fenimore Christopher R. |
SVP Controller |
|
2023-03-23 |
4 |
AS |
$806.47 |
$1,767,782 |
D/D |
(2,192) |
18,409 |
|
-9% |
|
Larosa Joseph J |
EVP General Counsel and Secret |
|
2023-03-10 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,006 |
0 |
|
- |
|
Mccourt Marion |
EVP Commercial |
|
2023-03-01 |
4 |
AS |
$759.89 |
$835,879 |
D/D |
(1,100) |
20,803 |
|
-7% |
|
2414 Records found
|
|
Page 8 of 97 |
|
|